These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31711733)

  • 1. Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider.
    Sato Y; Bando H; Di Piazza M; Gowing G; Herberts C; Jackman S; Leoni G; Libertini S; MacLachlan T; McBlane JW; Pereira Mouriès L; Sharpe M; Shingleton W; Surmacz-Cordle B; Yamamoto K; van der Laan JW
    Cytotherapy; 2019 Nov; 21(11):1095-1111. PubMed ID: 31711733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumorigenicity assessment of human cell-processed therapeutic products.
    Yasuda S; Sato Y
    Biologicals; 2015 Sep; 43(5):416-21. PubMed ID: 26071041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.
    Stacey G; Andrews P; Asante C; Barbaric I; Barry J; Bisset L; Braybrook J; Buckle R; Chandra A; Coffey P; Crouch S; Driver P; Evans A; Gardner J; Ginty P; Goldring C; Hay DC; Healy L; Hows A; Hutchinson C; Jesson H; Kalber T; Kimber S; Leathers R; Moyle S; Murray T; Neale M; Pan D; Park BK; Rebolledo RE; Rees I; Rivolta MN; Ritchie A; Roos EJ; Saeb-Parsy K; Schröder B; Sebastian S; Thomas A; Thomas RJ; Turner M; Vallier L; Vitillo L; Webster A; Williams D
    Regen Med; 2018 Dec; 13(8):935-944. PubMed ID: 30488776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multisite studies for validation and improvement of a highly efficient culture assay for detection of undifferentiated human pluripotent stem cells intermingled in cell therapy products.
    Watanabe T; Yasuda S; Kusakawa S; Kuroda T; Futamura M; Ogawa M; Mochizuki H; Kikkawa E; Furukawa H; Nagaoka M; Sato Y
    Cytotherapy; 2021 Feb; 23(2):176-183. PubMed ID: 32978066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumorigenicity Assessment of Human Cancer Cell Lines Xenografted on Immunodeficient Mice as Positive Controls of Tumorigenicity Testing.
    Oh S; Gu EY; Han JS; Lee BS; Moon KS; Kim YB; Han KH
    Int J Toxicol; 2022 Dec; 41(6):476-487. PubMed ID: 36069520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumorigenicity studies for human pluripotent stem cell-derived products.
    Kuroda T; Yasuda S; Sato Y
    Biol Pharm Bull; 2013; 36(2):189-92. PubMed ID: 23370350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical biosafety evaluation of cell-based therapies: emerging global paradigms.
    Basu J; Assaf BT; Bertram TA; Rao M
    Toxicol Pathol; 2015 Jan; 43(1):115-25. PubMed ID: 25476796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products.
    Kawamata S; Kanemura H; Sakai N; Takahashi M; Go MJ
    J Clin Med; 2015 Jan; 4(1):159-71. PubMed ID: 26237025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of the international conference on manufacturing and testing of pluripotent stem cells.
    Abbot S; Agbanyo F; Ahlfors JE; Baghbaderani BA; Bartido S; Bharti K; Burke C; Carlsson B; Cavagnaro J; Creasey A; DiGiusto D; Francissen K; Gaffney A; Goldring C; Gorba T; Griffiths E; Hanatani T; Hayakawa T; Heki T; Hoogendoorn K; Kawamata S; Kimura H; Kirkeby A; Knezevic I; Lebkowski J; Lin S; Lin-Gibson S; Lubiniecki A; O'Shea O; Pera M; Petricciani J; Pigeau G; Ratcliffe A; Sato Y; Schumann GG; Shingleton W; Stacey Chair G; Sullivan S; Svendsen CN; Trouvin JH; Vandeputte J; Yuan BZ; Zoon K
    Biologicals; 2018 Nov; 56():67-83. PubMed ID: 30150108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy Products.
    Hayakawa T; Harris I; Joung J; Kanai N; Kawamata S; Kellathur S; Koga J; Lin YC; Maruyama Y; McBlane J; Nishimura T; Renner M; Ridgway A; Salmikangas P; Sakamoto N; Sato D; Sato Y; Toda Y; Umezawa A; Werner M; Wicks S
    Biologicals; 2016 Sep; 44(5):467-79. PubMed ID: 27461129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a common framework for defining ancillary material quality across the development spectrum.
    Ball O; Zylberberg C
    Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific considerations for the regulatory evaluation of cell therapy products.
    Petricciani J; Hayakawa T; Stacey G; Trouvin JH; Knezevic I
    Biologicals; 2017 Nov; 50():20-26. PubMed ID: 28888427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of human pluripotent stem cells in clinical treatment.
    Simonson OE; Domogatskaya A; Volchkov P; Rodin S
    Ann Med; 2015; 47(5):370-80. PubMed ID: 26140342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and Future Cell Therapy Standards and Guidelines.
    Atkins JW; West K; Kasow KA
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):839-855. PubMed ID: 31466608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to assess the mutagenic potential of cosmetic products without animal tests?
    Speit G
    Mutat Res; 2009 Aug; 678(2):108-12. PubMed ID: 19379833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Strategic considerations on the design and choice of animal models for non-clinical investigations of cell-based medicinal products].
    Lehmann J; Schulz RM; Sanzenbacher R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1215-24. PubMed ID: 26431722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.
    McGowan NWA; Campbell JDM; Mountford JC
    Methods Mol Biol; 2018; 1698():285-292. PubMed ID: 29076098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.